Introduction
Spinal cord injury (SCI), resulting in long-term and severe disability, influences the quality of life and triggers serious socio-economic consequences (McDonald and Sadowsky, 2002) . Multiple cascades of pathophysiological processes rapidly follow the primary injury (the initial mechanical trauma to spinal cord), leading to secondary neuronal damage that causes further dysfunction (Oyinbo, 2011) . The detrimental secondary events develop minutes to weeks after SCI, including loss of motor neurons, gliosis, inflammation and oxidative stress (Jia et al., 2012; Ren and Young, 2013) . It is known that effective restraint of secondary injury is important for minimizing loss of motor neurons and improving functional recovery following SCI.
The cytokine IL-19, as a unique Th2 interleukin first described in 2000, was originally placed in the IL-10 subfamily, which included IL-10, . IL-19 shared 20% amino acid similarity with IL-10 but is functionally distinct from these sub-family members and especially IL-10 (Gallagher et al., 2000; Sabat et al., 2007) . IL-19 signalled through a heterodimeric receptor composed of IL-20R1 and IL-20R2, which was also utilized by IL-20 and IL-24 (Dumoutier et al., 2001) . IL-19 reduced inflammation in TNBS-induced experimental colitis (Matsuo et al., 2015) and halted progression of experimental atherosclerosis (Ellison et al., 2013; Gabunia et al., 2016) . More importantly, it was reported that IL-19 treatment reduced brain infarction and alleviated neurological deficits in a mouse model of cerebral ischaemia (Xie et al., 2016) . In the CNS, IL-19 was an anti-inflammatory cytokine, produced by activated microglia, which acted negatively on microglia in an autocrine manner (Horiuchi et al., 2015) . In our work, we found that IL-19 and its receptor were up-regulated in the spinal cord of mice after injury. We hypothesized that IL-19 may be beneficial for locomotor functional recovery after SCI, and we tested effect of mouse recombinant IL-19 and investigated the underlying mechanism(s) in a mouse model of SCI.
Methods

Animals and study design
All animal care and experimental procedures complied with the Animals (Scientific Procedures) Act, 1986 of the UK Parliament, Directive 2010/63/EU of the European Parliament and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the Animal Ethical Committee of the Chinese People's Liberation Army General Hospital. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . IL-19 knockout mice were generated using the VelociGene method and identified by genotyping of tail DNA by PCR using specific primers as described earlier (Ellison et al., 2014) . All animals were on a C57BL/6 background, bred and housed under specific pathogen-free conditions. Experiment 1: Mice (male, 20-25 g, n = 11 in each group) were randomly divided into two groups as follows: shamoperated group and SCI group. Seven days post-injury, protein (n = 3 for Western blotting analysis) and mRNA expression (n = 8 for RT-PCR analysis) of IL-19, IL-20R1 and IL-20R2 was assayed in the peri-lesional tissues (5 mm length of the spinal cord centred at the injury site or equivalent area in sham-operated mice).
Experiment 2: Male C57BL/6 mice (20-25 g) were exposed to spinal cord trauma and treated i.p. with IL-19 (5 and 10 ng·g À1 body weight·day À1 , n = 7 in each group) (Ellison et al., 2013; Xie et al., 2016) , s.c.) (Hsu et al., 2012) . Locomotor function was monitored each day for 2 weeks (n = 7 in each group). Seven days post-injury, the mice were killed, and perilesional tissues were removed for several biochemical analyses (n = 7 for RT-PCR, n = 7 for immunofluorescence staining, n = 3 for Western blotting, n = 7 for measurement of malondialdehyde (MDA) and pro-inflammatory cytokines levels). Before injection i.p., mouse recombinant IL-19 was diluted in 0.0025% BSA in sterile PBS. Mouse recombinant IL-19 was used to generate anti-mIL-19 mAb (Monoclonal Rat IgG2B Clone 9C), according to standard protocols in our lab. The isotype of the selected antibody, IgG, was determined using an isotyping ELISA. The antibody was purified using protein A chromatography. The antibody was shown to have <0.5 EU·mg À1 endotoxin and be of >95% purity. Initial treatment was given 6 h after the trauma. Experiment 4: Wild-type mice and IL-19(À/À) mice (male, 20-25 g, n = 6 in each group) were given SCI, and locomotor function was monitored each day for 2 weeks.
Mouse model of spinal cord trauma
Mice received a mid-thoracic spinal contusion trauma as described in Jakeman et al. (2000) . Briefly, after the mice were fully anaesthetized (5% isoflurane in 30% O 2 /70% N 2 O), a partial vertebral laminectomy was performed at the mid-thoracic level (T9-10). The exposed dorsal spinal surface (T9 spinal level) was displaced a calibrated vertical distance (0.5 mm over~25 ms), to produce a moderate contusion SCI using the Infinite Horizons Impactor (60 kdyn; Precision Systems and Instrumentation, Fairfax Station, VA, USA). During the surgery, the mice were placed on a controlled heating pad to maintain temperature at 37 ± 1°C. After the surgery, the mice were hydrated with physiological saline (2 mL, s.c.). Their bladders were manually expressed twice daily, and hydration was monitored daily. Analgesia was provided with buprenorphine (0.1 mg·kg À1 ; Temgesic, Schering-Plough, Belgium) injected s,c, 30 min before surgery and then the same dose every 12 h for 3 days. Mice that underwent laminectomy only served as sham controls.
Assessment of locomotor function
Hindlimb motor function was evaluated using the Basso Mouse Scale (BMS) open field locomotor test by two raters blinded to the study design (Basso et al., 2006) . The BMS is a 10-point locomotor rating scale, in which the scores range from 0 (complete hindlimb paralysis) to 9 (normal locomotion) points and include the assessment of ankle movement, plantar placement, weight support, stepping, coordination, paw position and trunk stability. Each mouse was observed separately for 4 min per session, and BMS scores were recorded. The mice with a BMS score higher than 0 at 24 h after injury were excluded from future evaluation.
Quantitative RT-PCR
Samples of spinal cords and spleens were homogenized in Trizol reagent (Life Technologies, Carlsbad, CA), and total RNA was isolated in accordance with the manufacturer's instructions. The purity of total RNA was measured with a Nanodrop 1000 spectrophotome-212-ter (Thermo Fisher Scientific, Waltham, MA), and the wavelength absorption ratio (260/280) was between 1.8 and 2.0 for all preparations.
Reverse transcription was carried out with 1 μg total RNA using the Superscript First-Strand Synthesis System for RT-PCR (Invitrogen), and RT-PCR was performed with a QuantiTectTM SYBR® Green PCR (TIANGEN BIOTECH, Beijing, China). Samples were analysed in triplicate, and expression of GAPDH mRNA was used as reference gene to normalize data, and then the final results were related to the calibrator samples (sham-operated group or vehicle-treated group) using the formula 2 -ΔΔCt . The sequences of primers were listed in Table 1 .
Western blotting analysis
Proteins from peri-lesional tissues were extracted using RIPA (PBS containing 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 0.5 mM PMSF, 500 ng/mL Leupeptin, 1 μg/mL aprotinin, 2.5 μg/mL pepstatin A). The primary antibodies used were anti-IL-19 (Abcam, Cambridge, UK), anti-IL-20R1 (Abcam), anti-IL-20R2 (Abcam), anti-platelet endothelial cell adhesion molecule-1 (anti-PECAM-1) (Abcam), anti-VEGF-A (Abcam) and anti-haem oxygenase 1 (anti-HO-1) (Abcam). Subsequently, the Western blot membranes were incubated with a HRP-coupled secondary antibody (GE Healthcare). Visualization was achieved by applying Supersignal West Pico-(Thermo Scientific) chemiluminescence HRP substrate, and band intensity was quantified by using the software Quantity One (version 4.5.2; Bio-Rad).
Immunofluorescence
Peri-lesional tissue sections (8 μm), taken from mice killed 7 days post-SCI, were used for immunofluorescence studies with antibodies specific for glial fibrillary acidic protein (GFAP) (Abcam), ionized calcium-binding adapter molecule 1 (IBA1) (Abcam), NeuN (Cell Signalling Technology) and CD68 (Abcam). Six sections per animal were analysed.
Representative images of each sample were acquired by using a fluorescence microscope (Leica DM5500B with digital camera Leica DFC345 FX, Leica Microsystems, Germany) for immunolabelling quantification. Quantification of GFAP, Iba-1 and CD68 expression was performed by intensity
analysis using ImageJ open source software (NIH) within rectangular areas of 100 μm × 100 μm.
Measurement of pro-inflammatory cytokines and VEGF-A
The peri-lesional tissues were homogenized in ice-cold RIPA containing 1% phenylmethanesulfonyl fluoride (Beyotime Institute of Biotechnology, Shanghai, China). The protein concentration was determined using Bradford dye-binding method (Beyotime Institute of Biotechnology). TNF-α, the chemokine CCL2 and VEGF-A levels in peri-lesional tissues were determined by using ELISA kits (TNF-α and VEGF-A, R&D Systems, Minneapolis, MN, USA; CCL2, Thermo Fisher Scientific).
Lipid peroxidation determination
MDA, an intermediate product of lipid peroxidation, was determined by the thiobarbituric acid method with a kit (Cayman, Ann Arbor, MI, USA). Protein quantification was used for data normalization.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . In the current study, data are shown as the means ± SD. The data except BBB scores were analysed by one-way ANOVA followed by a post hoc Tukey test to compare the control and treatment groups. Comparison of BBB scores among groups was analysed using a twoway ANOVA followed by Bonferroni t-test. Following the ANOVA, post hoc tests were run only if F achieved the necessary level of statistical significance (P < 0.05) and there was no significant variance in homogeneity. Statistical significance was accepted for P < 0.05. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/2018 (Alexander et al., 2017a,b) .
Results
Expression of IL-19 and its receptor (experiment one)
To elucidate the role of IL-19 in SCI, we first examined whether the injury affected the expression of IL-19 and its receptor in the spinal cord. Seven days after spinal cord trauma, the mRNA ( Figure 1A ) and protein ( Figure 1B ) of IL-19 and its receptor IL-20R1 and IL-20R2 were higher in the injured spinal cord than that in sham-operated mice.
Locomotor function (experiments two and three)
To evaluate the effect of treatment of IL-19 on recovery of locomotor function, the BMS scoring was applied. As expected, SCI led to complete paralysis of hindlimbs (BMS score 0) 24 h after injury with slow recovery of locomotor function during the following 2 weeks. In experiment two, treatment with exogenous IL-19 promoted the recovery of locomotor function in a dose-dependent manner ( Figure 2A) . In experiment three, IL-19 blocking antibody treatment abolished the effects of exogenous IL-19 on functional recovery in SCI mice ( Figure 2B ).
Loss of motor neurons and microglial and glial activation (experiment three)
To Figure 3E ) and protein ( Figure 3F ) levels of GFAP and IBA1 in injured spinal cords. Exogenous IL-19 also protected against loss of 
Immune modulation (experiment three)
As shown in the results of immunofluorescence staining and RT-PCR, treatment of SCI mice with IL-19 reduced the staining intensity of CD68-positive cells ( Figure 4A , B) and mRNA expression ( Figure 4C ) of CD68, indicating that IL-19 treatment reduced macrophage accumulation in SCI lesions. Furthermore, treatment of SCI mice with IL-19 reduced protein levels of TNF-α ( Figure 4D ) and CCL2 ( Figure 4E ) in the injured region. Our results suggested that IL-19 treatment suppressed inflammation following SCI, which was abolished by IL-19 blocking antibody. The immune status in whole spleen of mice of two groups was evaluated by measurement of the expression of Th1 and Th2 markers by RT-PCR. The spleens were rapidly removed from mice at the end of our study. Whole spleen lysates from IL-19-treated mice had significantly lower mRNA expression of the Th1 markers T-bet ( Figure 4F ) and higher mRNA expression of GATA-3 ( Figure 4G ).
Treatment with IL-19 reduced mRNA expression of IFN-γ ( Figure 4H , a Th1 marker), IL-12 ( Figure 4I ), inducible NOS (M1 markers, Figure 4J ) and enhanced mRNA expression of arginase-1 (Arg1) (Figure 4K ), Ym1 ( Figure 4M ) and CD206 ( Figure 4N , M2 markers) in the injured spinal cord. In addition, whole spleen lysates from IL-19-treated mice had significantly lower mRNA expression of IFN-γ and IL-12 and higher mRNA expression of Arg1, Ym1 and CD206. Our results suggested that IL-19 treatment promoted a shift towards a Th2 response following SCI, which was abolished by treatment with IL-19 blocking antibody.
Angiogenesis (experiment three)
To evaluate the effect of treatment of IL-19 on angiogenesis following SCI, expression of VEGF and PECAM-1 was determined. The predominant isoforms of VEGF in the CNS of mice were VEGF 120 , VEGF 164 and VEGF 188 (Figley et al., 2014) . It was found that treatment of SCI mice with IL-19 up-regulated mRNA expression of VEGF 120 and VEGF 164 ( Figure 5A ) in the injured spinal cord but had no significant effect on mRNA expression of VEGF 188 . Furthermore, Western blotting analysis revealed that treatment of SCI mice with IL-19 enhanced protein levels of PECAM-1 ( Figure 5B ) and VEGF-A ( Figure 5C ) in the injured spinal cord. Our results suggested that IL-19 promoted angiogenesis through upregulating VEGF expression following SCI, which was abolished by treatment with IL-19 blocking antibody.
Oxidative stress (experiment three)
Western blotting and RT-PCR analysis revealed that treatment of SCI mice with IL-19 up-regulated protein ( Figure 6A) and mRNA ( Figure 6B ) expression of HO-1 in the injured spinal cord. Furthermore, treatment of SCI mice with IL-19 reduced levels of MDA ( Figure 6C , marker of lipid peroxidation) in the injured region. Our results suggested that IL-19 decreased oxidative stress through up-regulating HO-1 expression following SCI, which was abolished by treatment with IL-19 blocking antibody.
Effect of IL-19 deficiency on locomotor function following SCI (experiment four)
To further confirm the role of IL-19 in the recovery from SCI, locomotor function was examined directly in IL-19 (À/À) mice and wild-type mice. All the mice had a BMS score of 9 pre-injury and a score of 0 1 day after surgery, with bilateral hindlimb paralysis. However, in mice with IL-19 deleted,
Figure 3
Effects of treatment with IL-19 (10 ng·g À1 ·day
À1
) and IL-19 blocking antibody (10 mg·kg À1 ·day
) on loss of motor neurons and microglial and glial activation in mice exposed to SCI. Sections (2 mm rostral to the epicentre, scale bar = 50 μm) were immuno-stained with antibodies recognizing NeuN (A), activated glial (GFAP, B) and microglia (IBA1, C) and the corresponding quantification (D). The mRNA (E) and protein (F) expressions of NeuN, GFAP and IBA1 were determined by quantitative real-time PCR and Western blotting respectively. Data shown are the means ± SD; n = 7 in each group. *P < 0.05, significantly different from the vehicle-treated group; #P < 0.05, significantly different from the IL-19-treated group.
Figure 4
Immune modulation of treatment with IL-19 (10 ng·g À1 ·day À1 ) and IL-19 blocking antibody (10 mg·kg À1 ·day À1 ) in mice with SCI. Representative micrographs (A) and corresponding quantification (B) of lumbar spinal cord sections (2 mm rostral to epicentre, scale bar = 50 μm) stained for immunofluorescence using antibody recognizing CD68 are shown. Graphs show the mRNA levels of CD68 (C) and protein levels of TNF-α (D) and CCL2 (E) in spinal cord, mRNA levels of T-bet (F) and GATA-3 (G) in spleen, and mRNA levels of IFN-γ (H), IL-12 (I), inducible NOS (iNOS) (J), Arg1 (K), Ym1 (M) and CD206 (N) in spinal cord and spleen of mice. Data shown are the means ± SD; n = 7 in each group. *P < 0.05, significantly different from the vehicle-treated group; #P < 0.05, significantly different from the IL-19-treated group.
Figure 5
Effects of treatment with IL-19 (10 ng·g À1 ·day À1 ) and IL-19 blocking antibody (10 mg·kg À1 ·day À1 ) on angiogenesis in spinal cord of mice exposed to SCI. Graphs show the mRNA levels (n = 7) of three isoforms of VEGF (A, VEGF 120 , VEGF 164 , and VEGF 188 ) in the injured spinal cords. In (B), Western blotting results and the corresponding quantification (B, n = 3) of PECAM-1 are shown. VEGF-A protein levels (C, n = 7) in spinal cord were determined by ELISA. Data shown are the means ± SD. *P < 0.05, significantly different from the vehicle-treated group; #P < 0.05, significantly different from the IL-19-treated group.
Figure 6
Effects of treatment with IL-19 (10 ng·g À1 ·day À1 ) and IL-19 blocking antibody (10 mg·kg À1 ·day À1 ) on oxidative stress in spinal cord of mice exposed to SCI. In (A), Western blotting results and the corresponding quantification (n = 3) of HO-1 are shown. Graphs show the mRNA levels (n = 7) of HO-1 (B) and the levels of MDA (C ) in the injured spinal cords. Data shown are the means ± SD. *P < 0.05, significantly different from the vehicle-treated group; #P < 0.05, significantly different from the IL-19-treated group.
the recovery of locomotor function following SCI was clearly delayed (Figure 7) .
Discussion
In the present study, we provided evidence that IL The local inflammatory micro-environment mediated by activated microglia and astrocytes and macrophages derived from infiltrating monocytes contributes greatly to the progression of secondary injury following SCI (Hayakawa et al., 2014; Plemel et al., 2014) . Exposure of macrophages to Th1 cytokines, such as IFN-γ and TNF-α, resulted in their polarization to the M1 subpopulation (the classical activated pro-inflammatory macrophages), which was detrimental in SCI (Sharma et al., 2003; Kigerl et al., 2009) . By contrast, the 'alternatively activated anti-inflammatory' M2 macrophages, induced by Th2 cytokines such as IL-4, IL-10 and IL-13, promoted axonal regeneration after CNS injury Francos-Quijorna et al., 2016) . In the injured spinal cord, the polarization of microglia/macrophages was M1 predominant and lasted longer . IL-19 was reported to be anti-inflammatory because in T-lymphocytes, it promoted the Th2, rather than the Th1 response (Gallagher et al., 2004; Gallagher, 2010) . In experimental models of atherosclerosis, splenocytes from IL-19-treated mice showed immune cell Th2 polarization, and plaque characterization showed an enrichment in markers of M2 macrophages (Ellison et al., 2013; Gabunia et al., 2016) . When compared with vehicle-injected controls, IL-19-treated mice had increased expression of M2 markers Richards et al., 2015) . In the current study, treatment of SCI mice with IL-19 promoted Th2 cytokine synthesis and led to the polarization of spinal macrophages/microglial cells towards an M2 phenotype, ultimately shifting the immune imbalance towards anti-inflammation that was conducive to the rescue of residual myelin and neurons and preservation of neuronal function.
Angiogenesis after SCI promoted endogenous repair and supported neural regeneration (Figley et al., 2014; Yu et al., 2016) . In the aortic ring model of angiogenesis and the hindlimb ischaemia induced by femoral artery ligation Richards et al., 2015) , IL-19 increased angiogenesis. In the current study, treatment of SCI mice with IL-19 increased expression of PECAM-1, which suggested that IL-19 promoted angiogenesis in the injured spinal cord. Macrophages polarized towards an M2 phenotype expressed a considerable number of angiogenic growth factors and had a higher angiogenic potential compared with other subsets (Jetten et al., 2014) , which could partly explain the angiogenic potential of IL-19. Accumulating evidence revealed that VEGF-A, known to promote the proliferation of endothelial cells and initiate angiogenesis, was a primary driver of neovascularization and had neuroprotective effects (Shweiki et al., 1992) . In bone marrow-derived macrophages, IL-19 treatment induced expression of VEGF-A Richards et al., 2015) . In the current study, treatment with IL-19 enhanced mRNA expression of VEGF 120 and VEGF 164 , and protein levels of VEGF-A. Additionally, IL-19 expression and activity were not restricted to leukocytes as IL-19 was also expressed in angiogenic tissue and has potent pro-angiogenic effects on many human endothelial cell types, including those from umbilical vein, coronary artery and the microvasculature (Jain et al., 2011) .
In the current study, treatment with exogenous IL-19 upregulated expression of HO-1 in the injured spinal cord. This enzyme is rate limiting in the conversion of the pro-oxidant haem to equimolar quantities of the potent antioxidant biliverdin, which was rapidly converted to bilirubin, as well as carbon monoxide (Maines, 2000) . HO-1 was expressed in the vascular compartment and in recruited neutrophils after SCI, and HO-1 induction attenuated neutrophil infiltration and microglial activation and decreased oxidative stress in the injured spinal cord (Hervera et al., 2012; Lin et al., 2016) . IL-19 induced expression of HO-1 and protected
Figure 7
Effects of knockout of the IL-19 gene on locomotor function in mice exposed to spinal cord trauma. The time courses of locomotor recovery evaluated by the 9-point BMS scoring after SCI are shown. Data shown are the means ± SD; n = 6 in each group. *P < 0.05, significantly different from the wild-type mice. IL-19 and spinal cord injury cultured vascular smooth muscle cells from ROS-induced and starvation-induced apoptosis (Gabunia et al., 2012) . In the current study, IL-19 decreased oxidative stress, as shown by reduced lipid peroxidation, which could contribute to upregulation of HO-1 and the reduced infiltration of macrophages in injured spinal cord.
In conclusion, IL-19 treatment reduced secondary injuries and improved locomotor functional recovery after contusion SCI, through many different mechanisms, including immune cell polarization, angiogenesis and anti-oxidative response (Figure 8) . Thus, IL-19 may be envisaged as a therapeutic strategy for patients with acute contusion SCI, but more work in animals and patients is required.
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